1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT
Primary Purpose
Glaucoma, Ocular Hypertension
Status
Terminated
Phase
Phase 3
Locations
Mexico
Study Type
Interventional
Intervention
Travoprost/Brinzolamide
Cosopt
Sponsored by
About this trial
This is an interventional treatment trial for Glaucoma focused on measuring glaucoma, Patients with open-angle glaucoma or ocular hypertension
Eligibility Criteria
Inclusion Criteria:
IOP at screening visit <18mmHg in at least one eye Mean IOP in same eye (at both eligibility 1 &2 visits)
- 24 and ≤ 36 mmHg at 9:00
- 21 and ≤ 36 mmHg at 11:00 and 16:00
Exclusion Criteria:
- Severe central visual field loss Angle Shaffer grade < 2 C/D ratio > 0.8 (horizontal or vertical measurement)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Active Comparator
Arm Label
Travoprost/Brinzolamide PM, Vehicle AM
Travoprost/Brinzolamide AM, Vehicle PM
Cosopt
Arm Description
Travoprost/Brinzolamide PM, Vehicle AM
Travoprost/Brinzolamide AM, Vehicle PM
Cosopt BID
Outcomes
Primary Outcome Measures
Mean IOP
Secondary Outcome Measures
Percent change in IOP, IOP change from baseline, patients with IOP <18mmHg. BSCVA, Ocular signs, Dilated fundus, perimetry, pachymetry, cardiovascular parameters(pulse, BP and AEs at W2, W3, M6, M9 and M12.
Full Information
NCT ID
NCT00767481
First Posted
October 3, 2008
Last Updated
July 18, 2012
Sponsor
Alcon Research
Collaborators
PPD
1. Study Identification
Unique Protocol Identification Number
NCT00767481
Brief Title
1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT
Study Type
Interventional
2. Study Status
Record Verification Date
November 2011
Overall Recruitment Status
Terminated
Why Stopped
Project Cancelled
Study Start Date
October 2008 (undefined)
Primary Completion Date
February 2009 (Actual)
Study Completion Date
February 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alcon Research
Collaborators
PPD
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Parallel, Multi-Center, Double-masked, Active controlled, three arm study comparing the IOP lowering efficacy and safety over 12 months of morning or evening instillations of Travoprost/Brinzolamide vs. Cosopt dosed in the morning and evening in patients with open-angle glaucoma or ocular hypertension.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glaucoma, Ocular Hypertension
Keywords
glaucoma, Patients with open-angle glaucoma or ocular hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
6 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Travoprost/Brinzolamide PM, Vehicle AM
Arm Type
Experimental
Arm Description
Travoprost/Brinzolamide PM, Vehicle AM
Arm Title
Travoprost/Brinzolamide AM, Vehicle PM
Arm Type
Experimental
Arm Description
Travoprost/Brinzolamide AM, Vehicle PM
Arm Title
Cosopt
Arm Type
Active Comparator
Arm Description
Cosopt BID
Intervention Type
Drug
Intervention Name(s)
Travoprost/Brinzolamide
Intervention Description
Eye drop suspension, once daily
Intervention Type
Drug
Intervention Name(s)
Cosopt
Intervention Description
Eye drop solution, one drop BID
Primary Outcome Measure Information:
Title
Mean IOP
Time Frame
9:00,11:00, and 1600 time points at month 12
Secondary Outcome Measure Information:
Title
Percent change in IOP, IOP change from baseline, patients with IOP <18mmHg. BSCVA, Ocular signs, Dilated fundus, perimetry, pachymetry, cardiovascular parameters(pulse, BP and AEs at W2, W3, M6, M9 and M12.
Time Frame
All on therapy time points not included in primary efficacy
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
IOP at screening visit <18mmHg in at least one eye Mean IOP in same eye (at both eligibility 1 &2 visits)
24 and ≤ 36 mmHg at 9:00
21 and ≤ 36 mmHg at 11:00 and 16:00
Exclusion Criteria:
Severe central visual field loss Angle Shaffer grade < 2 C/D ratio > 0.8 (horizontal or vertical measurement)
Facility Information:
City
Mexico City
ZIP/Postal Code
6700
Country
Mexico
12. IPD Sharing Statement
Learn more about this trial
1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT
We'll reach out to this number within 24 hrs